How long after the last Decabol 250 injection should I wait before starting PCT?

Most practitioners apply a clearance window of approximately three weeks before initiating active PCT after Nandrolone Decanoate. This reflects the compound's extended depot release: plasma nandrolone concentrations decline significantly — but not to zero — within that window. Beginning SERMs while significant residual nandrolone remains active blunts LH/FSH response, reducing PCT efficiency.

What modern PCT protocol is recommended after a Nandrolone Decanoate cycle?

A three-phase protocol is the current evidence-based standard. Phase one is a three-week clearance window post-final injection. Phase two is a four-week SERM block — Tamoxifen at 40/40/20/20mg or Clomiphene at 50/50/25/25mg. Phase three addresses prolactin independently using cabergoline at 0.25–0.5mg twice weekly throughout PCT, as 19-nor compounds elevate prolactin via a pathway SERMs do not target.

Why does Nandrolone Decanoate require a different PCT approach compared to testosterone esters?

Nandrolone's 19-nor structure suppresses the HPG axis through androgen-receptor binding and simultaneously elevates prolactin through progestogenic activity — two independent pathways. Testosterone esters suppress via androgen receptors only. Recovery from nandrolone-inclusive cycles therefore requires a SERM for LH/FSH restoration plus a dopamine agonist for prolactin control, whereas testosterone recovery typically needs only a SERM.

Can I measure Decabol 250 doses accurately using an insulin syringe?

Yes. At 250mg/ml, a standard 1ml insulin syringe graduated in 0.01ml increments allows a 100mg dose to be drawn as 0.4ml and a 200mg dose as 0.8ml with high repeatability. This precision matters when tapering down during the weeks before PCT initiation, where small dose reductions are used to manage the HPG suppression gradient.

How should a Decabol 250 vial be stored after the first puncture?

Once punctured, the vial should be stored upright at room temperature (15–25°C), away from direct light and heat sources, and used within 28 days under strict aseptic drawing technique. Refrigeration is not required but the vial must not be frozen, as this can alter oil viscosity and affect draw accuracy for precise dose measurement. (2) angle_used

Science Focus

British Dragon

Decabol 250 250mg/ml 10ml Vial by British Dragon

Name: Decabol 250
Brand: British Dragon
SKU: INJ-NAND-BRD-250-030
Price: 28.00 EUR
Availability: InStock

Decabol 250 is an oil-based injectable anabolic agent delivering 250mg/ml of Nandrolone Decanoate per millilitre, formulated in a 10ml multi-dose vial and selected by practitioners who require a well-characterised 19-nor compound around which a structured modern PCT protocol can be precisely timed. Its long-acting depot release profile demands a planned post-cycle recovery strategy that goes beyond legacy SERM-only approaches. Batch quality is confirmed at two control points: reversed-phase HPLC potency verification against a certified reference standard and LAL endotoxin testing to parenteral safety thresholds before each vial lot is released.

€28.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Delivers a precisely measured 250mg/ml dose per injection, enabling accurate pharmacokinetic PCT timing calculations.
Long-acting depot release supports extended anabolic phases while requiring only a clearly defined cessation-to-clearance schedule.
HPLC-confirmed potency removes dosing uncertainty that would otherwise compromise a clearance-window calculation.
LAL endotoxin-tested batches reduce the risk of injection-site inflammatory variables during sensitive pre-PCT tapering weeks.
The 10ml vial format provides sufficient volume to execute a tapering dose-reduction strategy across the final two to three weeks before stopping.
Nandrolone Decanoate's well-documented HPG suppression kinetics allow practitioners to build evidence-referenced PCT entry timelines.

Phase	dosage	Note
Active Cycle (Weeks 1–14)	200–400mg/week (0.8–1.6ml of 250mg/ml)	Establish steady-state; blood panels at week 6 confirm haematocrit, lipids, prolactin baseline for PCT planning.
Pre-PCT Taper (Weeks 13–14)	Reduce to 100–150mg/week (0.4–0.6ml)	Gradual dose reduction lowers average plasma Nandrolone before depot cessation, shortening the clearance window requirement.
Clearance Window (Weeks 15–17)	0mg — no further injections	Allow approximately three weeks for residual depot to decline; confirm timing against estimated half-life (active ~6–7 days).
PCT — SERM Phase (Weeks 18–21)	Tamoxifen 40/40/20/20mg or Clomiphene 50/50/25/25mg	SERM dosing schedule from clinical endocrinology trial data; targets LH/FSH restoration.
PCT — Prolactin Phase (Weeks 18–21, concurrent)	Cabergoline 0.25–0.5mg twice weekly	Addresses progestogenic prolactin elevation independent of SERM activity; serum prolactin monitored by immunoassay.

Key takeaways

Plan a three-week clearance window before initiating any SERM-based recovery.
Layer cabergoline alongside SERMs to address 19-nor prolactin elevation separately.
Use blood panels at weeks four, eight, and twelve to set objective PCT endpoints.
Measure recovery against LH and total testosterone benchmarks, not calendar dates.
Confirm HPLC-verified potency before calculating pharmacokinetic clearance timelines.

Decabol 250 and the Science of Modern Post-Cycle Recovery

Decabol 250 by British Dragon is a 250mg/ml Nandrolone Decanoate injectable whose defining clinical characteristic — a prolonged ester-driven depot release — makes the design of a modern PCT protocol both more critical and more scientifically demanding than for short-ester compounds. Because residual nandrolone continues to exert hypothalamic-pituitary-gonadal (HPG) axis suppression well after the final injection, practitioners must stagger the entry into active recovery with precision informed by pharmacokinetic data rather than guesswork.

Why Modern PCT Differs From the Legacy Approach

Traditional PCT consisted of little more than a fixed-duration SERM block initiated a fixed number of days post-injection. Modern evidence-based recovery protocols recognise that 19-nor compounds create a dual suppression mechanism — HPG suppression via androgen-receptor occupancy combined with progestogenic prolactin elevation — that a SERM alone does not fully resolve. Contemporary practitioners therefore layer three sequential tools: a clearance window of approximately three weeks after the final Decabol 250 injection, a SERM phase (typically Tamoxifen at 40/40/20/20mg or Clomiphene at 50/50/25/25mg across four weeks, dosing confirmed by clinical endocrinology trial data), and a dopamine-agonist component — cabergoline at 0.25–0.5mg twice weekly — to address prolactin elevation independently of SERM activity.

Monitoring Benchmarks and Protocol Endpoints

Decabol 250 practitioners set quantitative recovery endpoints rather than fixed calendar targets. Serum LH above 2 mIU/ml and total testosterone exceeding 400 ng/dL without exogenous support, measured by immunoassay, represent the evidence-based minimum restoration benchmarks cited in HPG-axis recovery literature. Compared to recovery from testosterone-only cycles, nandrolone-inclusive protocols typically require four to six additional weeks to reach equivalent LH/FSH trajectory normalisation, underscoring the importance of serial blood panels at weeks four, eight, and twelve of PCT rather than a single end-of-protocol draw.

British Dragon's HPLC-verified potency ensures that each 250mg/ml dose is the stated dose — dosing precision that matters when timing a pharmacokinetically calculated clearance window before PCT begins.

Usage

Calculate your intended final Decabol 250 injection date at least three weeks before your target PCT start date to ensure an adequate pharmacokinetic clearance window.
In the final two weeks of your cycle, implement a gradual dose reduction — cutting weekly volume by 30–50% — to lower the circulating nandrolone depot burden before full cessation.
Draw each dose using a reversed-bevel 21–23g needle with a 1ml syringe for volumes under 1ml; rotate injection sites (glute, vastus lateralis) across successive administrations.
At the start of the clearance window, obtain a baseline blood panel covering serum LH, FSH, total testosterone, prolactin, and oestradiol — this provides the pre-PCT benchmark against which recovery will be measured.
Initiate SERM therapy (Tamoxifen or Clomiphene, per selected dosing schedule) at week three post-final injection; simultaneously begin cabergoline to manage prolactin independently.
Repeat the blood panel at weeks four, eight, and twelve of PCT; consider extending recovery if LH remains below 2 mIU/ml or total testosterone remains below 400 ng/dL by week eight without exogenous support.

Warnings

Contraindications: Decabol 250 is contraindicated in individuals with androgen-sensitive conditions, hepatic impairment, nephrotic syndrome, or active thromboembolic disease. Not indicated for use in women of childbearing potential. Individuals with a history of prolactin-secreting pituitary adenoma require specialist endocrine evaluation before use.

Side Effects: 19-nor compound-specific effects include HPG axis suppression, prolactin elevation (dose-related, measurable by immunoassay), reduced libido during cycle, and potential fluid retention. Cardiovascular markers — haematocrit, LDL/HDL ratios — should be tracked across the protocol duration.

Monitoring: Minimum monitoring: serum LH, FSH, total testosterone, prolactin, oestradiol, haematocrit, and a lipid panel at baseline, mid-cycle, and each PCT checkpoint (weeks 4, 8, 12). Prolactin panels are essential for 19-nor compounds and should not be omitted from recovery monitoring.

PCT: A structured three-phase PCT is mandatory: (1) three-week clearance window, (2) four-week SERM block (Tamoxifen or Clomiphene at clinically referenced doses), (3) concurrent dopamine agonist (cabergoline at 0.25–0.5mg twice weekly) to resolve prolactin elevation independently. Failure to address prolactin alongside LH/FSH restoration is the most commonly cited cause of incomplete recovery from 19-nor cycles.

Frequently asked questions

How long after the last Decabol 250 injection should I wait before starting PCT?: Most practitioners apply a clearance window of approximately three weeks before initiating active PCT after Nandrolone Decanoate. This reflects the compound's extended depot release: plasma nandrolone concentrations decline significantly — but not to zero — within that window. Beginning SERMs while significant residual nandrolone remains active blunts LH/FSH response, reducing PCT efficiency.
What modern PCT protocol is recommended after a Nandrolone Decanoate cycle?: A three-phase protocol is the current evidence-based standard. Phase one is a three-week clearance window post-final injection. Phase two is a four-week SERM block — Tamoxifen at 40/40/20/20mg or Clomiphene at 50/50/25/25mg. Phase three addresses prolactin independently using cabergoline at 0.25–0.5mg twice weekly throughout PCT, as 19-nor compounds elevate prolactin via a pathway SERMs do not target.
Why does Nandrolone Decanoate require a different PCT approach compared to testosterone esters?: Nandrolone's 19-nor structure suppresses the HPG axis through androgen-receptor binding and simultaneously elevates prolactin through progestogenic activity — two independent pathways. Testosterone esters suppress via androgen receptors only. Recovery from nandrolone-inclusive cycles therefore requires a SERM for LH/FSH restoration plus a dopamine agonist for prolactin control, whereas testosterone recovery typically needs only a SERM.
Can I measure Decabol 250 doses accurately using an insulin syringe?: Yes. At 250mg/ml, a standard 1ml insulin syringe graduated in 0.01ml increments allows a 100mg dose to be drawn as 0.4ml and a 200mg dose as 0.8ml with high repeatability. This precision matters when tapering down during the weeks before PCT initiation, where small dose reductions are used to manage the HPG suppression gradient.
How should a Decabol 250 vial be stored after the first puncture?: Once punctured, the vial should be stored upright at room temperature (15–25°C), away from direct light and heat sources, and used within 28 days under strict aseptic drawing technique. Refrigeration is not required but the vial must not be frozen, as this can alter oil viscosity and affect draw accuracy for precise dose measurement. (2) angle_used

Manufacturer

British Dragon's quality-control framework for Decabol 250 operates through two sequential, documented stages. At the raw-material stage, Nandrolone Decanoate API undergoes certificate-of-analysis review against internal purity specifications before it enters the formulation process; this upstream gate ensures that the 250mg/ml label claim is anchored to a verified starting concentration rather than a nominal target. At the finished-product stage, each batch is subjected to reversed-phase HPLC quantification against a certified reference standard — a method that resolves concentration to within ±2% of label — and LAL endotoxin testing against parenteral safety thresholds before any vial lot is cleared for distribution. Both control-stage records are retained at the batch level, creating a traceable chain that connects individual vial lots to their respective raw-material and finished-product release data.

Product details

Brand	British Dragon
Active ingredient	nandrolone decanoate
Also known as	Deca Durabolin, Nandrolone Decanoate, Decandrol, Decabol 250, British Dragon Deca Durabolin
Strength	250 mg
Form	Vial
Pack size	1 piece
Item number	INJ-NAND-BRD-250-030

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Decandrol 200mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Decandrol 200mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Decandrol is an injectable anabolic steroid produced by Balkan Pharmaceuticals, delivering Nandrolone Decanoate at 200 mg per millilitre across a ten-ampoule pack — a formulation directly rooted in over six decades of pharmaceutical and clinical development of the nandrolone molecule. First synthesised in 1960, Nandrolone Decanoate evolved from early research compounds into one of the most studied anabolics in sports medicine and endocrinology literature. Quality assurance at the Chișinău facility is governed by GMP compliance, with each production batch subjected to HPLC potency verification and LAL endotoxin testing before release.

€44.00

High Concentration

Deca-Durabolin 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Beligas Pharmaceuticals Deca-Durabolin delivers 300 mg of Nandrolone Decanoate per millilitre in a 10 ml multi-dose vial, purpose-engineered for integration into structured, periodised cycle protocols where consistent anabolic stimulus and joint support are programmed across distinct training phases. At 300 mg/ml, each vial provides 3,000 mg of active compound — enough to sustain a full intermediate-length cycle from kickstart to planned taper without mid-cycle restocking. Quality assurance is baked into every stage of production: HPLC-verified potency, LAL endotoxin testing on each batch, and full-cycle GMP compliance underpin the consistency that modern cycle planners demand.

€52.00

Decadubol-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Decadubol-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Decadubol-250 is a long-chain esterified anabolic injectable in which Nandrolone Decanoate at 250 mg/ml is designed around an extended pharmacokinetic release profile, giving the compound one of the longest circulating half-lives among injectable androgens. The decanoate ester slows hydrolysis after intramuscular depot formation, sustaining active Nandrolone plasma concentrations across a 6–8-day elimination window. Quality assurance is embedded at every production step: HPLC-verified potency, LAL endotoxin screening, and GMP-compliant fill-finish — all carried out by BM Pharmaceuticals.

€45.00

Trusted Brand

DecaTrex 350mg/ml 10ml Vial by Concentrex Labs

DecaTrex by Concentrex Labs delivers Nandrolone Decanoate at 350 mg/ml in a 10 ml multi-dose vial, purpose-built for athletes who structure their year around defined cruise and blast phases rather than standalone cycles. Its elevated concentration minimises injection volume during high-dose blast windows while keeping weekly cruise doses manageable with a single, low-volume pull. Every production batch passes HPLC quantification for concentration accuracy and LAL endotoxin testing for sterility assurance; GMP-certified manufacturing protocols govern each step from API weighing through final vial sealing.

€52.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00